<DOC>
	<DOC>NCT02667938</DOC>
	<brief_summary>The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction</brief_summary>
	<brief_title>A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules</brief_title>
	<detailed_description>A multicenter, randomized, double-blind, phase 3 clinical trial to evaluate the efficacy and safety of HCP1303 capsule</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>At Visit 1 1. ≥50 age 2. BPH(Benign Prostatic Hyperplasia) + Total IPSS(International Prostate Symptom Score) ≥ 13 3. Abnormal Erectile function ≥ at least 3months based on screening date At Visit 2 1. Total IPSS ≥ 13 1. History of hypersensitivity to Tamsulosin or Tadalafil 2. History of allergy for Sulfonamide 3. PSA (Prostate Specific Antigen) ≥4ng/mL</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>